Skip to main content
Publications
Neches V, Campbell K, Coll P, Moreno Guillen S, Martinez-Sesmero JM, Lopez Segui F, O'Brien P, Davis A, Anderson SJ, Schroeder M, Vallejo-Aparicio LA. Cost-effectiveness of cabotegravir long-acting for pre-exposure prophylaxis versus current use of daily oral tenofovir disoproxil fumarate/emtricitabine or no prep to prevent HIV-1 in individuals at high risk in Spain. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S121. doi: 10.1016/j.jval.2024.10.620
Desai A, Dong OM, Gautier S, Johnson T, Wong A, Osman AMY, Harvey J, Tran TH, Holladay Ford DM, Kerr KW, Aggarwal A, Mauskopf J. A systematic review of health economic evaluations of oral nutritional supplements as a single-component or multi-component intervention in older adults with or at risk of malnutrition. Poster presented at the ISPOR Europe 2024; November 18, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12):S120.
Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. What is the medical technology HTA process in Japan? Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S284. doi: 10.1016/j.jval.2024.03.1554
Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. HTA requirements for medical technologies in Canada. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S286. doi: 10.1016/j.jval.2024.03.1564
Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer unselected for DDR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772
Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer with HRR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S119. doi: 10.1016/j.jval.2023.09.772
